181 related articles for article (PubMed ID: 21654207)
1. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.
Mariotte D; Dupont B; Gervais R; Galais MP; Laroche D; Tranchant A; Comby E; Bouhier-Leporrier K; Reimund JM; Le Mauff B
MAbs; 2011; 3(4):396-401. PubMed ID: 21654207
[TBL] [Abstract][Full Text] [Related]
2. Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab.
Serrier J; Davy JB; Dupont B; Clarisse B; Parienti JJ; Petit G; Khoy K; Ollivier Y; Gervais R; Mariotte D; Le Mauff B
BMC Cancer; 2023 Jan; 23(1):32. PubMed ID: 36624467
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
Chung CH; Mirakhur B; Chan E; Le QT; Berlin J; Morse M; Murphy BA; Satinover SM; Hosen J; Mauro D; Slebos RJ; Zhou Q; Gold D; Hatley T; Hicklin DJ; Platts-Mills TA
N Engl J Med; 2008 Mar; 358(11):1109-17. PubMed ID: 18337601
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B; Mariotte D; Dugué AE; Clarisse B; Grellard JM; Babin E; Chauffert B; Dakpé S; Moldovan C; Bouhier-Leporrier K; Reimund JM; Di Fiore F; Zanetta S; Mailliez A; Do P; Peytier A; Galais MP; Florescu C; Schott R; Le Mauff B; Gervais R
Br J Clin Pharmacol; 2017 Mar; 83(3):623-631. PubMed ID: 27662818
[TBL] [Abstract][Full Text] [Related]
5. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
[TBL] [Abstract][Full Text] [Related]
6. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
7. Alpha-Gal-containing biologics and anaphylaxis.
Chinuki Y; Morita E
Allergol Int; 2019 Jul; 68(3):296-300. PubMed ID: 31053502
[TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Dupont B; Mariotte D; Clarisse B; Galais MP; Bouhier-Leporrier K; Grellard JM; Le Mauff B; Reimund JM; Gervais R
Future Oncol; 2014 Nov; 10(14):2133-40. PubMed ID: 25471028
[TBL] [Abstract][Full Text] [Related]
9. Immunologic evaluation of immediate hypersensitivity to cefaclor.
Yoo HS; Kim SH; Kwon HS; Kim TB; Nam YH; Ye YM; Park HS
Yonsei Med J; 2014 Nov; 55(6):1473-83. PubMed ID: 25323882
[TBL] [Abstract][Full Text] [Related]
10. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection.
Park KH; Lee J; Beom SH; Shin SJ; Ahn JB; Kim SR; Lee JH; Park JW
World Allergy Organ J; 2021 Jul; 14(7):100553. PubMed ID: 34257795
[TBL] [Abstract][Full Text] [Related]
11. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
12. Proper Cut-off Levels of Serum Specific IgE to Cefaclor for Patients with Cefaclor Allergy.
Nam YH; Lee SH; Rhyou HI; Lee YS; Park SH; Lee YH; Shin YS; Park HS; Ye YM
Yonsei Med J; 2018 Oct; 59(8):968-974. PubMed ID: 30187704
[TBL] [Abstract][Full Text] [Related]
13. Rat monoclonal anti-murine IgE antibody removes IgE molecules already bound to mast cells or basophilic leukemia cells, resulting in the inhibition of systemic anaphylaxis and passive cutaneous anaphylaxis.
Miyajima H; Watanabe N; Ovary Z; Okumura K; Hirano T
Int Arch Allergy Immunol; 2002 May; 128(1):24-32. PubMed ID: 12037398
[TBL] [Abstract][Full Text] [Related]
14. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
15. Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.
Fischer J; Eberlein B; Hilger C; Eyer F; Eyerich S; Ollert M; Biedermann T
Allergy; 2017 May; 72(5):764-771. PubMed ID: 27775867
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.
Iwamoto T; Okamoto A; Ishinaga H; Shimizu K; Gayle AA; Arai N; Takeuchi K; Okuda M
Cancer Med; 2016 Jun; 5(6):1004-12. PubMed ID: 26880699
[TBL] [Abstract][Full Text] [Related]
17. Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.
Weiss J; Grilley Olson J; Deal AM; Chera B; Weissler M; Murphy BA; Hayes DN; Gilbert J
Cancer; 2016 Jun; 122(11):1697-701. PubMed ID: 26989991
[TBL] [Abstract][Full Text] [Related]
18. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab.
Baudouin V; Crusiaux A; Haddad E; Schandene L; Goldman M; Loirat C; Abramowicz D
Transplantation; 2003 Aug; 76(3):459-63. PubMed ID: 12923429
[TBL] [Abstract][Full Text] [Related]
19. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
20. How to manage hypersensitivity reactions to biological agents?
Barbaud A; Granel F; Waton J; Poreaux C
Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
